Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHICS: Casodex 150mg for Biochemical Failure in Prostate Cancer
NCT00554086Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2005
- Primary completion
- Sep 2009
- Countries
- 1
- Sponsor
- Canadian Urology Research Consortium
- Drugs
- bicalutamide
- Conditions
- prostate cancer (PCa)
01
Overview
Phase 2, open-label trial of bicalutamide in prostate cancer (PCa), sponsored by Canadian Urology Research Consortium. Primary endpoint: Time to PSA Doubling at 1 year. Started Nov 2005; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Endpoints
Primary
Time to PSA Doubling
Beyond the preview
Go deeper on NCT00554086.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00554086.